USC/Norris Comprehensive Cancer Center
USC/Norris
About USC/Norris
Patient Care
Research
Clinical Trials
Search Trials
Faculty
Education
Future at USC/Norris
Core Facilities
Support USC/Norris
» Contact Us
» Glossary
» Make a Donation
If you are a patient, please contact
The Doctors of USC
at 800-USC-CARE.
Details for trial 3C-06-1
Description:
A Pilot Study to Evaluate the Safety and Efficacy of Aprepitant in Combination with Dolasetron and Dexamethasone for the Prevention of Nausea and Vomiting Following Oxaliplatin-Containing Regimen Which Includes 5-FU.
Status:
Open
Randomized?
Yes
Researchers
Principal Investigator
Title
Betty M. Chan
Pharm.D.
Data Management
Name
Title
Anayansi Miloud
D.M.
You may participate in this study if:
Requirement
1
18 y/o and above.
2
With metastatic or unresectable colorectal cancer scheduled to receive initial Treatment with FOLFOX ± Bevacizumab
3
Standard anti-emetics with initial treatment must include Dolasetron and Dexamethasone.
4
Must agree to keep a journal of nausea, vomiting, retching and rescue medications used on days 1-5.
5
Signed Informed Consent (including HIPAA authorization).
You may not participate in this study if:
1
With allergy or intolerance to Dolasetron & Dexamethasone.
2
Had other anti-emetics w/in 72 hrs (5HT3 antagonists, phenothiazines, butyrophenones, cannabinoids, metoclopramide, corticosteroids).
3
Had vomiting or retching w/in 24 hrs.
4
With severe concurrent illness.
5
With gastrointestinal obstruction or active peptic ulcer.
6
Had radiotherapy to abdomen or pelvis w/in 1 wk before and after day 1.
7
Absoluite Neutophil Count <1500, Platelets <100,000 (unless approved to proceed w/chemotherapy)
8
AST, ALT, Bilrubini or Alkaline Phosphatase >2x ULN.
9
Pregnant or nursing.
10
Non-English speaking.
For further information on, or to sign up for this study, please contact the Clinical Investigation Support Office at (323) 865-0451 or the Principal Investigator noted above.
